Sigrid Therapeutics
Quotes
Share:
Subscribe:

Tore Bengtsson founder headshot

Mon, Aug 18, 2025 08:00 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Sigrid Therapeutics to Present SHINE Trial Results at EASD 2025 Annual Meeting Tue, Jun 03, 2025 08:00 CET

Sigrid Therapeutics Completes Enrollment in SHINE to Evaluate SiPore21® Gel for Sustained Blood Sugar and Weight Management Tue, Jul 30, 2024 08:30 CET

Sigrid Therapeutics Surpasses the 50% Enrollment Milestone in its Clinical Trial, SHINE, to Evaluate the SiPore21® Gel for Sustained Diabetes and Obesity Control Tue, Apr 30, 2024 08:30 CET